Bill Text: TX SB1645 | 2013-2014 | 83rd Legislature | Introduced
Bill Title: Relating to the addition of certain substances to Penalty Group 3 of the Texas Controlled Substances Act; providing penalties.
Spectrum: Partisan Bill (Republican 1-0)
Status: (Introduced - Dead) 2013-03-20 - Referred to Criminal Justice [SB1645 Detail]
Download: Texas-2013-SB1645-Introduced.html
83R11924 DDT-D | ||
By: Williams | S.B. No. 1645 |
|
||
|
||
relating to the addition of certain substances to Penalty Group 3 of | ||
the Texas Controlled Substances Act; providing penalties. | ||
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
SECTION 1. Section 481.104(a), Health and Safety Code, is | ||
amended to read as follows: | ||
(a) Penalty Group 3 consists of: | ||
(1) a material, compound, mixture, or preparation that | ||
contains any quantity of the following substances having a | ||
potential for abuse associated with a stimulant effect on the | ||
central nervous system: | ||
Methylphenidate and its salts; and | ||
Phenmetrazine and its salts; | ||
(2) a material, compound, mixture, or preparation that | ||
contains any quantity of the following substances having a | ||
potential for abuse associated with a depressant effect on the | ||
central nervous system: | ||
a substance that contains any quantity of a | ||
derivative of barbituric acid, or any salt of a derivative of | ||
barbituric acid not otherwise described by this subsection; | ||
a compound, mixture, or preparation containing | ||
amobarbital, secobarbital, pentobarbital, or any salt of any of | ||
these, and one or more active medicinal ingredients that are not | ||
listed in any penalty group; | ||
a suppository dosage form containing amobarbital, | ||
secobarbital, pentobarbital, or any salt of any of these drugs, and | ||
approved by the United States Food and Drug Administration for | ||
marketing only as a suppository; | ||
Alprazolam; | ||
Amobarbital; | ||
Bromazepam; | ||
Camazepam; | ||
Carisoprodol; | ||
Chlordiazepoxide; | ||
Chlorhexadol; | ||
Clobazam; | ||
Clonazepam; | ||
Clorazepate; | ||
Clotiazepam; | ||
Cloxazolam; | ||
Delorazepam; | ||
Diazepam; | ||
Estazolam; | ||
Ethyl loflazepate; | ||
Etizolam; | ||
Fludiazepam; | ||
Flurazepam; | ||
Glutethimide; | ||
Halazepam; | ||
Haloxzolam; | ||
Ketazolam; | ||
Loprazolam; | ||
Lorazepam; | ||
Lormetazepam; | ||
Lysergic acid, including its salts, isomers, and | ||
salts of isomers; | ||
Lysergic acid amide, including its salts, | ||
isomers, and salts of isomers; | ||
Mebutamate; | ||
Medazepam; | ||
Methyprylon; | ||
Midazolam; | ||
Nimetazepam; | ||
Nitrazepam; | ||
Nordiazepam; | ||
Oxazepam; | ||
Oxazolam; | ||
Pentazocine, its salts, derivatives, or compounds | ||
or mixtures thereof; | ||
Pentobarbital; | ||
Phenazepam; | ||
Pinazepam; | ||
Prazepam; | ||
Quazepam; | ||
Secobarbital; | ||
Sulfondiethylmethane; | ||
Sulfonethylmethane; | ||
Sulfonmethane; | ||
Temazepam; | ||
Tetrazepam; | ||
Tiletamine and zolazepam in combination, and its | ||
salts. (some trade or other names for a tiletamine-zolazepam | ||
combination product: Telazol, for tiletamine: 2-(ethylamino)- | ||
2-(2-thienyl)-cyclohexanone, and for zolazepam: 4-(2- | ||
fluorophenyl)-6, 8-dihydro-1,3,8,-trimethylpyrazolo-[3,4- | ||
e](1,4)-d diazepin-7(1H)-one, flupyrazapon); | ||
Triazolam; | ||
Zaleplon; | ||
Zolpidem; and | ||
Zopiclone; | ||
(3) Nalorphine; | ||
(4) a material, compound, mixture, or preparation | ||
containing limited quantities of the following narcotic drugs, or | ||
any of their salts: | ||
not more than 1.8 grams of codeine, or any of its | ||
salts, per 100 milliliters or not more than 90 milligrams per dosage | ||
unit, with an equal or greater quantity of an isoquinoline alkaloid | ||
of opium; | ||
not more than 1.8 grams of codeine, or any of its | ||
salts, per 100 milliliters or not more than 90 milligrams per dosage | ||
unit, with one or more active, nonnarcotic ingredients in | ||
recognized therapeutic amounts; | ||
not more than 300 milligrams of dihydrocodeinone | ||
(hydrocodone), or any of its salts, per 100 milliliters or not more | ||
than 15 milligrams per dosage unit, with a fourfold or greater | ||
quantity of an isoquinoline alkaloid of opium; | ||
not more than 300 milligrams of dihydrocodeinone | ||
(hydrocodone), or any of its salts, per 100 milliliters or not more | ||
than 15 milligrams per dosage unit, with one or more active, | ||
nonnarcotic ingredients in recognized therapeutic amounts; | ||
not more than 1.8 grams of dihydrocodeine, or any | ||
of its salts, per 100 milliliters or not more than 90 milligrams per | ||
dosage unit, with one or more active, nonnarcotic ingredients in | ||
recognized therapeutic amounts; | ||
not more than 300 milligrams of ethylmorphine, or | ||
any of its salts, per 100 milliliters or not more than 15 milligrams | ||
per dosage unit, with one or more active, nonnarcotic ingredients | ||
in recognized therapeutic amounts; | ||
not more than 500 milligrams of opium per 100 | ||
milliliters or per 100 grams, or not more than 25 milligrams per | ||
dosage unit, with one or more active, nonnarcotic ingredients in | ||
recognized therapeutic amounts; | ||
not more than 50 milligrams of morphine, or any of | ||
its salts, per 100 milliliters or per 100 grams with one or more | ||
active, nonnarcotic ingredients in recognized therapeutic amounts; | ||
and | ||
not more than 1 milligram of difenoxin and not | ||
less than 25 micrograms of atropine sulfate per dosage unit; | ||
(5) a material, compound, mixture, or preparation that | ||
contains any quantity of the following substances: | ||
Barbital; | ||
Chloral betaine; | ||
Chloral hydrate; | ||
Ethchlorvynol; | ||
Ethinamate; | ||
Meprobamate; | ||
Methohexital; | ||
Methylphenobarbital (Mephobarbital); | ||
Paraldehyde; | ||
Petrichloral; and | ||
Phenobarbital; | ||
(6) Peyote, unless unharvested and growing in its | ||
natural state, meaning all parts of the plant classified | ||
botanically as Lophophora, whether growing or not, the seeds of the | ||
plant, an extract from a part of the plant, and every compound, | ||
manufacture, salt, derivative, mixture, or preparation of the | ||
plant, its seeds, or extracts; | ||
(7) unless listed in another penalty group, a | ||
material, compound, mixture, or preparation that contains any | ||
quantity of the following substances having a stimulant effect on | ||
the central nervous system, including the substance's salts, | ||
optical, position, or geometric isomers, and salts of the | ||
substance's isomers, if the existence of the salts, isomers, and | ||
salts of isomers is possible within the specific chemical | ||
designation: | ||
Benzphetamine; | ||
Cathine [(+)-norpseudoephedrine]; | ||
Chlorphentermine; | ||
Clortermine; | ||
Diethylpropion; | ||
Fencamfamin; | ||
Fenfluramine; | ||
Fenproporex; | ||
Mazindol; | ||
Mefenorex; | ||
Modafinil; | ||
Pemoline (including organometallic complexes and | ||
their chelates); | ||
Phendimetrazine; | ||
Phentermine; | ||
Pipradrol; | ||
Sibutramine; and | ||
SPA [(-)-1-dimethylamino-1,2-diphenylethane]; | ||
(8) unless specifically excepted or unless listed in | ||
another penalty group, a material, compound, mixture, or | ||
preparation that contains any quantity of the following substance, | ||
including its salts: | ||
Dextropropoxyphene (Alpha-(+)-4-dimethylamino- | ||
1,2-diphenyl-3-methyl-2-propionoxybutane); and | ||
(9) an anabolic steroid, including any drug or | ||
hormonal substance, or any substance that is chemically or | ||
pharmacologically related to testosterone, other than an estrogen, | ||
progestin, dehydroepiandrosterone, or corticosteroid, and promotes | ||
muscle growth, including the following drugs and substances and any | ||
salt, ester, or ether of the following drugs and substances: | ||
Androstanediol; | ||
Androstanedione; | ||
Androstenediol; | ||
Androstenedione; | ||
Bolasterone; | ||
Boldenone; | ||
Calusterone; | ||
Clostebol; | ||
Dehydrochlormethyltestosterone; | ||
Delta-1-dihydrotestosterone; | ||
Dihydrotestosterone (4-dihydrotestosterone); | ||
Drostanolone; | ||
Ethylestrenol; | ||
Fluoxymesterone; | ||
Formebulone; | ||
Furazabol; | ||
13beta-ethyl-17beta-hydroxygon-4-en-3-one; | ||
4-hydroxytestosterone; | ||
4-hydroxy-19-nortestosterone; | ||
Mestanolone; | ||
Mesterolone; | ||
Methandienone; | ||
Methandriol; | ||
Methenolone; | ||
17alpha-methyl-3beta, 17 beta-dihydroxy-5alpha- | ||
androstane; | ||
17alpha-methyl-3alpha, 17 beta-dihydroxy-5alpha- | ||
androstane; | ||
17alpha-methyl-3beta, 17beta-dihydroxyandrost-4- | ||
ene; | ||
17alpha-methyl-4-hydroxynandrolone; | ||
Methyldienolone; | ||
Methyltestosterone; | ||
Methyltrienolone; | ||
17alpha-methyl-delta-1-dihydrotestosterone; | ||
Mibolerone; | ||
Nandrolone; | ||
Norandrostenediol; | ||
Norandrostenedione; | ||
Norbolethone; | ||
Norclostebol; | ||
Norethandrolone; | ||
Normethandrolone; | ||
Oxandrolone; | ||
Oxymesterone; | ||
Oxymetholone; | ||
Stanozolol; | ||
Stenbolone; | ||
Testolactone; | ||
Testosterone; | ||
Tetrahydrogestrinone; and | ||
Trenbolone. | ||
SECTION 2. The change in law made by this Act applies only | ||
to an offense committed on or after the effective date of this Act. | ||
An offense committed before the effective date of this Act is | ||
governed by the law in effect on the date the offense was committed, | ||
and the former law is continued in effect for that purpose. For | ||
purposes of this section, an offense was committed before the | ||
effective date of this Act if any element of the offense occurred | ||
before that date. | ||
SECTION 3. This Act takes effect September 1, 2013. |